Differentiated product
Omega-3 fatty acids
Oral solution · Hypertriglyceridaemia
Product data
- Dosage form
- Oral solution
- Dosage-form group
- Oral liquid
- Therapeutic area
- Hypertriglyceridaemia
- Reference product
- Suspension 1000 mg (EPA + DHA + quercetin)
- Status
- Ready for commercialisation
- Development stage
- 5 of 5 · Ready for commercialisation
- Portfolio
- Differentiated product
Note: Source reads “Read for Commercials”V-20
Start a conversation
Where does your programme stand?
Tell us the molecule, the dosage form and the market you are filing in. A programme lead will read it and reply with what we would do next.
Business enquiries: vasanthi@kmshc.com · +91 97898 75194V-23